Previous 10 | Next 10 |
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead The Q4 earnings season cranks up with Procter & Gamble (NYSE:PG), Netflix (NASDAQ:NFLX) and Intel (NASDAQ:INTC) some...
Four IPOs are scheduled to raise $1.8 billion in the shortened holiday week, featuring a diverse group of foreign issuers. China's leading e-cigarette brand RLX Technology plans to raise $1.0 billion at a $14.0 billion market cap. Street research is expected for Inhibikase Therape...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
CAMBRIDGE, Mass. and GOSSELIES, Belgium, Jan. 05, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, tod...
CAMBRIDGE, Mass. and GOSSELIES, Belgium, Nov. 23, 2020 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, tod...
iTeos Therapeutics (ITOS): Q3 GAAP EPS of -$0.48 misses by $0.11.Csh and equivalent position was $340M.Press Release For further details see: iTeos Therapeutics EPS misses by $0.11
- Patient enrol l ment in Phase 1/2 stud ies of EOS-850 A 2A R antagonist and EOS-448 FCγ R-enabled anti-TIGIT antibody continue s with initial data expected in 1H21 - - Strong cash position to support ongoing clinical...
CAMBRIDGE, Mass. and GOSSELIES, Belgium, Nov. 12, 2020 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, tod...
CAMBRIDGE, Mass. and GOSSELIES, Belgium, Nov. 05, 2020 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, tod...
CAMBRIDGE, Mass. and GOSSELIES, Belgium, Sept. 08, 2020 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, to...
News, Short Squeeze, Breakout and More Instantly...
iTeos Therapeutics Inc. Company Name:
ITOS Stock Symbol:
NASDAQ Market:
iTeos Therapeutics Inc. Website:
WATERTOWN, Mass. and GOSSELIES, Belgium, July 08, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today a...
2024-05-22 01:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-13 07:00:04 ET Swayampakula Ramakanth from H.C. Wainwright issued a price target of $46.00 for ITOS on 2024-05-13 06:11:00. The adjusted price target was set to $46.00. At the time of the announcement, ITOS was trading at $17.44. ITOS currently trades -32.51% ver...